Moreover, p53 mutations in CAFs of breast and prostate cancer patients, whose cancer cells maintain wild-type p53 function, were associated with an increased rate of metastasis and poor prognosis [5,58,59,61]. The gene discussed is TP53; the disease is prostate carcinoma.